Prelude Therapeutics Inc
NASDAQ:PRLD
Cash Flow Statement
Cash Flow Statement
Prelude Therapeutics Inc
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||||
| Net Income |
(38)
|
(48)
|
(57)
|
(78)
|
(84)
|
(98)
|
(112)
|
(120)
|
(120)
|
(120)
|
(115)
|
(114)
|
(117)
|
(117)
|
(122)
|
(126)
|
(130)
|
(132)
|
(127)
|
(128)
|
(124)
|
(112)
|
|
| Depreciation & Amortization |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
|
| Stock-Based Compensation |
2
|
3
|
6
|
9
|
13
|
18
|
21
|
24
|
26
|
25
|
25
|
25
|
25
|
26
|
26
|
25
|
24
|
23
|
21
|
20
|
17
|
14
|
|
| Other Non-Cash Items |
2
|
3
|
6
|
10
|
13
|
20
|
24
|
27
|
30
|
31
|
29
|
28
|
27
|
25
|
24
|
22
|
21
|
21
|
18
|
18
|
17
|
14
|
|
| Change in Working Capital |
3
|
5
|
5
|
5
|
7
|
5
|
4
|
2
|
1
|
1
|
1
|
(7)
|
(13)
|
(15)
|
(10)
|
(7)
|
4
|
4
|
4
|
3
|
(3)
|
(4)
|
|
| Cash from Operating Activities |
(33)
N/A
|
(40)
-21%
|
(46)
-16%
|
(62)
-35%
|
(63)
-2%
|
(73)
-15%
|
(84)
-15%
|
(89)
-7%
|
(88)
+2%
|
(87)
+2%
|
(84)
+3%
|
(92)
-10%
|
(101)
-10%
|
(106)
-5%
|
(107)
-1%
|
(109)
-2%
|
(104)
+4%
|
(106)
-2%
|
(103)
+3%
|
(105)
-2%
|
(108)
-3%
|
(100)
+8%
|
|
| Investing Cash Flow | |||||||||||||||||||||||
| Capital Expenditures |
(1)
|
(0)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(3)
|
(2)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
(260)
|
(261)
|
(219)
|
(201)
|
81
|
85
|
61
|
(31)
|
(38)
|
(31)
|
(18)
|
82
|
78
|
91
|
122
|
107
|
136
|
|
| Cash from Investing Activities |
(1)
N/A
|
(0)
+36%
|
(1)
-27%
|
(2)
-160%
|
(2)
-16%
|
(262)
-13 928%
|
(264)
-1%
|
(221)
+16%
|
(204)
+8%
|
79
N/A
|
82
+4%
|
58
-29%
|
(34)
N/A
|
(41)
-19%
|
(35)
+16%
|
(21)
+38%
|
80
N/A
|
76
-5%
|
90
+19%
|
121
+34%
|
107
-12%
|
136
+28%
|
|
| Financing Cash Flow | |||||||||||||||||||||||
| Net Issuance of Common Stock |
30
|
248
|
247
|
408
|
379
|
162
|
165
|
4
|
3
|
3
|
1
|
1
|
111
|
111
|
136
|
136
|
26
|
26
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
|
| Other |
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Financing Activities |
30
N/A
|
247
+734%
|
246
0%
|
408
+66%
|
379
-7%
|
162
-57%
|
165
+2%
|
3
-98%
|
3
-2%
|
3
-18%
|
1
-69%
|
0
-51%
|
111
+27 745%
|
111
0%
|
136
+23%
|
137
+0%
|
25
-81%
|
25
-1%
|
(0)
N/A
|
(0)
-122%
|
(0)
-8%
|
(0)
+44%
|
|
| Change in Cash | |||||||||||||||||||||||
| Net Change in Cash |
(4)
N/A
|
207
N/A
|
199
-4%
|
344
+73%
|
313
-9%
|
(173)
N/A
|
(182)
-5%
|
(307)
-68%
|
(288)
+6%
|
(5)
+98%
|
(1)
+77%
|
(33)
-2 639%
|
(24)
+27%
|
(36)
-49%
|
(5)
+85%
|
7
N/A
|
1
-79%
|
(5)
N/A
|
(13)
-169%
|
16
N/A
|
(2)
N/A
|
36
N/A
|
|
| Free Cash Flow | |||||||||||||||||||||||
| Free Cash Flow |
(34)
N/A
|
(40)
-20%
|
(47)
-16%
|
(64)
-37%
|
(65)
-2%
|
(75)
-15%
|
(86)
-14%
|
(92)
-7%
|
(90)
+1%
|
(89)
+1%
|
(87)
+3%
|
(95)
-9%
|
(104)
-10%
|
(109)
-5%
|
(111)
-1%
|
(112)
-1%
|
(106)
+5%
|
(108)
-1%
|
(104)
+4%
|
(106)
-2%
|
(109)
-3%
|
(100)
+8%
|
|